| PAVLASOVÁ, Gabriela, Marek BORSKÝ, Kateřina MUSILOVÁ, Václav ŠEDA, Kateřina ČERNÁ, Jitka OSIČKOVÁ, Eva VOJÁČKOVÁ, Yvona BRYCHTOVÁ, Michael DOUBEK, Šárka POSPÍŠILOVÁ, Jiří MAYER a Marek MRÁZ. Rituximab preferentially eliminates BCR signaling proficient chronic lymphocytic leukemia B cells In Vivo. In Blood (2016); s. 2030. (58th ASH Annual Meeting and Exposition, San Diego, USA, prosinec 2016). 2016. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1364763,
author = {Pavlasová, Gabriela and Borský, Marek and Musilová, Kateřina and Šeda, Václav and Černá, Kateřina and Osičková, Jitka and Vojáčková, Eva and Brychtová, Yvona and Doubek, Michael and Pospíšilová, Šárka and Mayer, Jiří and Mráz, Marek},
booktitle = {Blood (2016); s. 2030. (58th ASH Annual Meeting and Exposition, San Diego, USA, prosinec 2016)},
title = {Rituximab preferentially eliminates BCR signaling proficient chronic lymphocytic leukemia B cells In Vivo},
year = {2016}
}
TY - CONF
ID - 1364763
AU - Pavlasová, Gabriela - Borský, Marek - Musilová, Kateřina - Šeda, Václav - Černá, Kateřina - Osičková, Jitka - Vojáčková, Eva - Brychtová, Yvona - Doubek, Michael - Pospíšilová, Šárka - Mayer, Jiří - Mráz, Marek
PY - 2016
TI - Rituximab preferentially eliminates BCR signaling proficient chronic lymphocytic leukemia B cells In Vivo
ER -
PAVLASOVÁ, Gabriela, Marek BORSKÝ, Kateřina MUSILOVÁ, Václav ŠEDA, Kateřina ČERNÁ, Jitka OSIČKOVÁ, Eva VOJÁČKOVÁ, Yvona BRYCHTOVÁ, Michael DOUBEK, Šárka POSPÍŠILOVÁ, Jiří MAYER a Marek MRÁZ. Rituximab preferentially eliminates BCR signaling proficient chronic lymphocytic leukemia B cells In Vivo. In \textit{Blood (2016); s. 2030. (58th ASH Annual Meeting and Exposition, San Diego, USA, prosinec 2016)}. 2016.
|
